SXTC
China SXT Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
7.72 / 10
Outperform
Capital flow is strong (7.72/10) with positive trends across overall, block, small, medium, large, and extra-large flows, suggesting liquidity support. However, analyst coverage is sparse (no detailed ratings provided), and the recent news of a 1-for-150 share consolidation could pressure sentiment and price. The combination of robust fund inflows and limited analyst input creates a neutral-to-cautious outlook.
Fund Flow Rating
What is the analyst consensus for SXTC?
- SXTC holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 7.72/10 (Outperform).
